Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4642 + AG + Adebrelimab in Pancreatic Cancer
NCT07131514Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Aug 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HRS-4642 in pancreatic cancer (PC), sponsored by Ruijin Hospital. Primary endpoints: Adverse events and Objective Response Rate up to 6 months. Started Aug 2025; status: recruiting.
02
Drugs
HRS-4642
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07131514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07131514.